Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tiffany Zigras

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Current Oncology (Toronto, Ont.)|September 27, 2023
Bevacizumab Treatment for Low-Grade Serous Ovarian Cancer: A Systematic ReviewCaitlin Lazurko, Revital Linder, Kate Pulman, et al.
Journal of Obstetrics and Gynaecology Canada : JOGC = Journal D'Obstetrique Et Gynecologie Du Canada : JOGC|January 7, 2021
Does Radical Hysterectomy for Clinically Apparent Stage II Endometrial Cancer Affect Risk of Local Recurrence?Genevieve K Lennox, Mitchell Clark, Tiffany Zigras, et al.
American Journal of Obstetrics and Gynecology|July 19, 2025
Association of frailty with healthcare utilization and days alive at home in patients with gynecologic cancers: a population-based studyJulie M V Nguyen, Tiffany Zigras, Anastasia Gayowsky, et al.
Gynecologic Oncology|June 8, 2025
Association of frailty with perioperative and survival outcomes in patients with gynecologic cancers: A population-based studyJulie M V Nguyen, Tiffany Zigras, Anastasia Gayowsky, et al.
Current Oncology (Toronto, Ont.)|June 27, 2023
Canadian Guideline on the Management of a Positive Human Papillomavirus Test and Guidance for Specific PopulationsTiffany Zigras, Marie-Hélène Mayrand, Celine Bouchard, et al.
Anaerobe|May 8, 2022
First reported case of Robinsoniella peoriensis pyometra and bloodstream infection: A case report and review of the literatureJavier Mejia-Gomez, Tiffany Zigras, Yashesh Patel, et al.
Climacteric : the Journal of the International Menopause Society|June 8, 2026
The use of menopause hormone therapy in borderline ovarian tumor survivors: a systematic review and meta-analysisJavier Mejia-Gomez, Melissa Tigert, Michelle Jacobson, et al.
Plos One|July 28, 2025
Frailty Assessment for Risk prediction in Gynecologic Oncology patients undergoing surgery and chemotherapy (FARGO) study protocol: Rationale and design of a multi-centre prospective cohort studyJulie My Van Nguyen, Danielle Vicus, Liat Hogen, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|February 12, 2015
Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitroLiancheng Zhu, Salvatore Lopez, Stefania Bellone, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Current Oncology (Toronto, Ont.)|September 27, 2023
Bevacizumab Treatment for Low-Grade Serous Ovarian Cancer: A Systematic ReviewCaitlin Lazurko, Revital Linder, Kate Pulman, et al.
Journal of Obstetrics and Gynaecology Canada : JOGC = Journal D'Obstetrique Et Gynecologie Du Canada : JOGC|January 7, 2021
Does Radical Hysterectomy for Clinically Apparent Stage II Endometrial Cancer Affect Risk of Local Recurrence?Genevieve K Lennox, Mitchell Clark, Tiffany Zigras, et al.
American Journal of Obstetrics and Gynecology|July 19, 2025
Association of frailty with healthcare utilization and days alive at home in patients with gynecologic cancers: a population-based studyJulie M V Nguyen, Tiffany Zigras, Anastasia Gayowsky, et al.
Gynecologic Oncology|June 8, 2025
Association of frailty with perioperative and survival outcomes in patients with gynecologic cancers: A population-based studyJulie M V Nguyen, Tiffany Zigras, Anastasia Gayowsky, et al.
Current Oncology (Toronto, Ont.)|June 27, 2023
Canadian Guideline on the Management of a Positive Human Papillomavirus Test and Guidance for Specific PopulationsTiffany Zigras, Marie-Hélène Mayrand, Celine Bouchard, et al.
Anaerobe|May 8, 2022
First reported case of Robinsoniella peoriensis pyometra and bloodstream infection: A case report and review of the literatureJavier Mejia-Gomez, Tiffany Zigras, Yashesh Patel, et al.
Climacteric : the Journal of the International Menopause Society|June 8, 2026
The use of menopause hormone therapy in borderline ovarian tumor survivors: a systematic review and meta-analysisJavier Mejia-Gomez, Melissa Tigert, Michelle Jacobson, et al.
Plos One|July 28, 2025
Frailty Assessment for Risk prediction in Gynecologic Oncology patients undergoing surgery and chemotherapy (FARGO) study protocol: Rationale and design of a multi-centre prospective cohort studyJulie My Van Nguyen, Danielle Vicus, Liat Hogen, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|February 12, 2015
Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitroLiancheng Zhu, Salvatore Lopez, Stefania Bellone, et al.
Pageof 2